|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang J, Espinoza LA, Kinders RJ, et al:
NANOG modulates stemness in human colorectal cancer. Oncogene.
October 22–2012.(Epub ahead of print). View Article : Google Scholar
|
|
3
|
Linderholm BK, Gruvberger-Saal S, Ferno M,
et al: Vascular endothelial growth factor is a strong predictor of
early distant recurrences in a prospective study of premenopausal
women with lymph-node negative breast cancer. Breast. 17:484–491.
2008. View Article : Google Scholar
|
|
4
|
Ezeh UI, Turek PJ, Reijo RA, et al: Human
embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are
expressed in both seminoma and breast carcinoma. Cancer.
104:2255–2265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bourguignon LY, Peyrollier K, Xia W and
Gilad E: Hyaluronan-CD44 interaction activates stem cell marker
Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated
multidrug efflux in breast and ovarian tumor cells. J Biol Chem.
283:17635–17651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
You JS, Kang JK, Seo DW, et al: Depletion
of embryonic stem cell signature by histone deacetylase inhibitor
in NCCIT cells: involvement of Nanog suppression. Cancer Res.
69:5716–5725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu CS, Li DX, Liu YH, et al: Expression
of NANOG in human gliomas and its relationship with
undifferentiated glioma cells. Oncol Rep. 26:593–601.
2011.PubMed/NCBI
|
|
8
|
Ranganathan R, Lu KP, Hunter T and Noel
JP: Structural and functional analysis of the mitotic rotamase Pin1
suggests substrate recognition is phosphorylation dependent. Cell.
89:875–886. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen M, Stukenberg PT, Kirschner MW and Lu
KP: The essential mitotic peptidyl-prolyl isomerase Pin1 binds and
regulates mitosis-specific phosphoproteins. Genes Dev. 12:706–720.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lam PB, Burga LN and Wu BP: Prolyl
isomerase Pin1 is highly expressed in Her2-positive breast cancer
and regulates erbB2 protein stability. Mol Cancer. 7:912008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuramochi J, Arai T and Ikeda S: High Pin1
expression is associated with tumor progression in colorectal
cancer. J Surg Oncol. 94:155–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ryo A, Hirai A and Nishi M: A suppressive
role of the prolyl isomerase Pin1 in cellular apoptosis mediated by
the death-associated protein Daxx. J Biol Chem. 282:36671–36681.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moretto-Zita M, Jin H and Shen Z:
Phosphorylation stabilizes Nanog by promoting its interaction with
Pin1. Proc Natl Acad Sci USA. 107:13312–13317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He H, Niu CS and Li MW: Correlation
between glioblastoma stem-like cells and tumor vascularization.
Oncol Rep. 27:45–50. 2012.PubMed/NCBI
|
|
15
|
Sotomayor P, Godoy A, Smith GJ and Huss
WJ: Oct4A is expressed by a subpopulation of prostate
neuroendocrine cells. Prostate. 69:401–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayala G, Wang D, Wulf G, et al: The prolyl
isomerase Pinl is a novel prognostic marker in human prostate
cancer. Cancer Res. 63:6244–6251. 2003.PubMed/NCBI
|
|
17
|
Bao L, Kimzey A, Sauter G, et al:
Prevalent overexpression of prolyl isomerase Pinl in human cancers.
Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sasaki T, Ryo A, Uemura H, et al: An
immunohistochemical scoring system of prolyl isomerase Pin1 for
predicting relapse of prostate carcinoma after radical
prostatectomy. Pathol Res Pract. 202:357–364. 2006. View Article : Google Scholar
|
|
19
|
Van Meir EG, Hadjipanayis CG, Norden AD,
et al: Exciting new advances in neuro-oncology: the avenue to a
cure for malignant glioma. CA Cancer J Clin. 60:166–193.
2010.PubMed/NCBI
|
|
20
|
Lu KP and Zhou XZ: The prolyl isomerase
PIN1: a pivotal new twist in phosphorylation signalling and
disease. Nat Rev Mol Cell Biol. 8:904–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saegusa M, Hashimura M and Kuwata T: Pin1
acts as a modulator of cell proliferation through alteration in
NF-kappaB but not β-catenin/TCF4 signalling in a subset of
endometrial carcinoma cells. J Pathol. 222:410–420. 2010.PubMed/NCBI
|
|
22
|
Luo Z, Wijeweera A, Oh Y, et al: Pin1
facilitates the phosphorylation-dependent ubiquitination of SF-1 to
regulate gonadotropin β-subunit gene transcription. Mol Cell Biol.
30:745–763. 2010.PubMed/NCBI
|
|
23
|
Nakano A, Koinuma D, Miyazawa K, et al:
Pin1 down-regulates transforming growth factor-β (TGF-β) signaling
by inducing degradation of Smad proteins. J Biol Chem.
284:6109–6115. 2009.PubMed/NCBI
|
|
24
|
Siepe D and Jentsch S: Prolyl isomerase
Pin1 acts as a switch to control the degree of substrate
ubiquitylation. Nat Cell Biol. 11:967–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicole Tsang YH, Wu XW, Lim JS, et al:
Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in
breast cancer. Oncogene. 32:1488–1496. 2012.PubMed/NCBI
|
|
26
|
Mei PJ, Bai J, Liu H, et al: RUNX3
expression is lost in glioma and its restoration causes drastic
suppression of tumor invasion and migration. J Cancer Res Clin
Oncol. 137:1823–1830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mueller W, Nutt CL, Ehrich M, et al:
Downregulation of RUNX3 and TES by hypermethylation in
glioblastoma. Oncogene. 26:583–593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akhoondi S, Sun D, von der Lehr N, et al:
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer
Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maser RS, Choudhury B, Campbell PJ, et al:
Chromosomally unstable mouse tumours have genomic alterations
similar to diverse human cancers. Nature. 447:966–971. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Strohmaier H, Spruck CH, Kaiser P, et al:
Human F-box protein hCdc4 targets cyclin E for proteolysis and is
mutated in a breast cancer cell line. Nature. 413:316–322. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Min SH, Lau AW, Lee TH, et al: Negative
regulation of the stability and tumor suppressor function of Fbw7
by the Pin1 prolyl isomerase. Mol Cell. 46:771–783. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryo A, Liou YC, Lu KP, et al: Prolyl
isomerase Pin1: a catalyst for oncogenesis and a potential
therapeutic target in cancer. J Cell Sci. 116:773–783. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitsui K, Tokuzawa Y, Itoh H, et al: The
homeoprotein Nanog is required for maintenance of pluripotency in
mouse epiblast and ES cells. Cell. 113:631–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan G and Thomson JA: Nanog and
transcriptional networks in embryonic stem cell pluripotency. Cell
Res. 17:42–49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pereira L, Yi F and Merrill BJ: Repression
of Nanog gene transcription by Tcf3 limits embryonic stem cell
self-renewal. Mol Cell Biol. 26:7479–7491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suzuki A, Raya A, Kawakami Y, et al:
Maintenance of embryonic stem cell pluripotency by Nanog-mediated
reversal of mesoderm specification. Nat Clin Pract Cardiovasc Med.
3:114–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siu MK, Wong ES, Kong DS, et al: Stem cell
transcription factor NANOG controls cell migration and invasion via
dysregulation of E-cadherin and FoxJ1 and contributes to adverse
clinical outcome in ovarian cancers. Oncogene. September
3–2012.(Epub ahead of print). View Article : Google Scholar
|
|
38
|
Singh SK, Clarke ID, Terasaki M, et al:
Identification of a cancer stem cell in human brain tumors. Cancer
Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
39
|
Huff CA, Matsui W, Smith BD and Jones RJ:
The paradox of response and survivalin cancer therapeutics. Blood.
107:431–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang L, Zhang X, Zhang M, et al: Increased
nanog expression promotes tumor development and Cisplatin
resistance in human esophageal cancer cells. Cell Physiol Biochem.
30:943–952. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye F, Zhou C, Cheng Q, et al:
Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are
highly expressed in malignant cervical epithelial cells. BMC
Cancer. 8:1082008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo Y, Liu S, Wang P, et al: Expression
profile of embryonic stem cell-associated genes Oct4, Sox2 and
Nanog in human gliomas. Histopathology. 59:763–775. 2011.
View Article : Google Scholar : PubMed/NCBI
|
